Herpes vector-mediated gene transfer in treatment of diseases of the nervous system

Annual Review of Microbiology

Volumn 58, Issue , 2004, Pages 253-271

  Glorioso, Joseph C ^a   Fink, David J ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Gene therapy; Glioblastoma; Neuropathy; Pain; Spinal cord injury

Indexed keywords

ANTIDIABETIC AGENT; ANTINOCICEPTIVE AGENT; CISPLATIN; ENKEPHALIN; GANCICLOVIR; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HERPESVIRUS VECTOR; METENKEPHALIN; MORPHINE; NALTREXONE; NERVE GROWTH FACTOR; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN SHN; PROTEIN SHPE; PROTEIN SLN; PYRIDOXINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; BRAIN TUMOR; CHRONIC PAIN; DISEASE MODEL; DRUG SAFETY; GENE CONSTRUCT; GENE DELETION; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMEDIATE EARLY GENE; INTRACTABLE PAIN; NEUROLOGIC DISEASE; PARENCHYMA; PARKINSON DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SPINAL GANGLION; TRANS ISOMER; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIOBLASTOMA; HUMANS; NERVE GROWTH FACTORS; NERVOUS SYSTEM DISEASES; SIMPLEXVIRUS; SPINAL CORD INJURIES;

DNA VIRUSES; HERPES; HERPESVIRIDAE; RODENTIA; SIMPLEXVIRUS;

EID: 9244259139     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.58.030603.123709     Document Type: Review

References (87)

1. Aloe L, Manni L, Properzi F, De Santis S, Fiore M. 2000. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton. Neurosci. 86:84-93
2. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, et al. 1997. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57:1502-9
3. Apfel SC. 2002. Is the therapeutic application of neurotrophic factors dead? Ann. Neurol. 51:8-11
4. Batterson W, Roizman B. 1983. Characterization of the herpes simplex virion-associated factor responsible for the induction of αgenes. J. Virol. 66:3573-82
5. Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. 2000. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc. Natl. Acad. Sci. USA 97:8146-50
6. Berthomme H, Lokensgard J, Yang L, Margolis T, Feldman LT. 2000. Evidence for a bidirectional element located down-stream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency. J. Virol. 74:3613-22
7. Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB. 2000. Potent analgesic effects of GDNF in neuropathic pain states. Science 290:124-27
8. Burton EA, Glorioso JC, Fink DJ. 2003. Gene therapy progress and prospects: Parkinson's disease. Gene. Ther. 10:1721-27
9. Campbell MEM, Palfeyman JW, Preston CM. 1984. Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J. Mol. Biol. 180:1-19
10. Cavaletti G, Cascinu S, Venturino P, Tedeschi M, Tredici G. 1996. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res. 16:3149-59
11. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-72
12. Chattopadhyay M, Goss J, Lacomis D, Goins W, Glorioso JC, et al. 2003. Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur. J. Neurosci. 17:732-40
13. Chattopadhyay M, Goss J, Wolfe D, Goins W, Huang S. 2004. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 127:929-39
14. Chattopadhyay M, Wolfe D, Huang S, Goss J, Glorioso J, et al. 2002. In vivo gene therapy of pyridoxine-induced neuropathy by HS V-mediated gene transfer of neurotrophin-3. Ann. Neurol. 51:19-27
15. Chen X, Li J, Mata M, Goss J, Wolfe D, et al. 2000. Herpes simplex virus type 1 ICPO protein does not accumulate in the nucleus of primary neurons in culture. J. Virol. 74:10132-41
16. Cohen SM, Lippard SJ. 2001. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67:93-130
17. Cook ML, Stevens JG. 1973. Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intra-axonal transport of infection. Infect. Immun. 7:272-88
18. Davidson BL, Breakefield XO. 2003. Viral vectors for gene delivery to the nervous system. Nat. Rev. Neurosci. 4:353-64
19. Dechant G. 2001. Molecular interactions between neurotrophin receptors. Cell. Tissue Res. 305:229-38
20. DiStefano PS, Friedman B, Radziejewski C, Alexander C, Boland P, et al. 1992. The neurotrophins BDNF, NT-3 and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 8:983-93
21. Dressler G, Rock D, Fraser N. 1987. Latent herpes simplex virus type 1 DNA is not extensively methylated in vivo. J. Gen. Virol. 68:1761-65
22. Dubuisson D, Dennis SG. 1977. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161-74
23. Ernfors P, Rosario CM, Merlio JP, Grant G, Aldskogius H, Persson H. 1993. Expression of mRNAs for neurotrophin receptors in the dorsal root ganglion and spinal cord during development and following peripheral or central axotomy. Brain Res. Mol. Brain Res. 17:217-26
24. Friedmann T, Roblin R. 1972. Gene therapy for human generic disease? Science 175:949-55
25. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. 1998. Entry of α herpes viruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280:1618-20
26. Goins WF, Lee KA, Cavalcoli JD, O'Malley ME, DeKosky ST, et al. 1999. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J. Virol. 73:519-32
27. Goins WF, Sternberg LR, Croen KD, Krause PR, Hendricks RL, et al. 1994. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J. Virol. 68:2239-52
28. Gold MS. 2000. Spinal nerve ligation: what to blame for the pain and why. Pain 84:117-20
29. Goss JR, Goins WC, Lacomis D, Mata M, Glorioso JC, et al. 2002. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 51:2227-32
30. Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, et al. 2002. Herpes vector-mediated expression of proenkephalin reduces pain-related behavior in a model of bone cancer pain. Ann. Neurol. 52:662-65
31. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. 2001. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther. 8:551-56
32. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. 2003. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. Pain 102:135-42
33. Hao S, Mata M, Wolfe D, Huang S, Glorioso J, Fink DJ. 2003. HSV-mediated gene transfer of the glial cell derived neurotrophic factor (GDNF) provides an anti-allodynic effect in neuropathic pain. Mol. Ther. 8:367-75
34. Harbour DA, Hill TJ, Blyth WA. 1983. Recurrent herpes simplex in the mouse: inflammation in the skin and activation of virus in the ganglia following peripheral stimulation. J. Gen. Virol. 64(Pt. 7): 1491-98
35. Helke CJ, Adryan KM, Fedorowicz J, Zhuo H, Park JS, et al. 1998. Axonal transport of neurotrophins by visceral afferent and efferent neurons of the vagus nerve of the rat. J. Comp. Neurol. 393:102-17
36. Honess RW, Roizman B. 1974. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J. Virol. 14:8-19
37. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, et al. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med. 6:521-28
38. Josephson A, Widenfalk J, Trifunovski A, Widmer HR, Olson L, Spenger C. 2001. GDNF and NGF family members and receptors in human fetal and adult spinal cord and dorsal root ganglia. J. Comp. Neurol. 440:204-17
39. Kim SH, Chung JM. 1992. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-63
40. Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL. 1999. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J. Immunol. 162:2895-905
41. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso JC. 1997. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther. 4:1120-25
42. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, et al. 1998. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 5:1517-30
43. Kwong AD, Frenkel N. 1989. The herpes simplex virus virion host shutoff function. J. Virol. 63:4834-39
44. Lachmann RH, Efstathiou S. 1997. Utilization of the herpes simplex virus type 1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system. J. Virol. 71:3197-207
45. Lynas C, Laycock KA, Cook SD, Hill TJ, Blyth WA, Maitland NJ. 1989. Detection of herpes simplex virus type 1 gene expression in latently and productively infected mouse ganglia using the polymerase chain reaction. J. Gen. Virol. 70:2345-55
46. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, et al. 2000. Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther. 1:71-81
47. Markert JM, Malick A, Coen DM, Martuza RL. 1993. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32:597-603
48. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, et al. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:867-74
49. Marshall KR, Lachmann RH, Efstathiou S, Rinaldi A, Preston CM. 2000. Longterm transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression. J. Virol. 74:956-64
50. Mata M, Glorioso JC, Fink DJ. 2003. Gene transfer to the nervous system: prospects for novel treatments directed at diseases of the aging nervous system. J. Gerontol. A Biol Sci. Med. Sci. 58: M1111-18
51. Mata M, Zhang M, Hu X, Fink DJ. 2001. HveC (nectin-1) is expressed at high levels in sensory neurons, but not in motor neurons, of the rat peripheral nervous system. J. Neurovirol 7:476-80
52. Mata M, Zhang M, Wolfe D, Hu J, Huang S, et al. 2003. Gene therapy for spinal cord hemisection injury using a replication incompetent HSV vector to deliver GDNF. Soc. Neurosci. Program No. 775.4
53. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, et al. 1988. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol. 69:1531-74
54. McGeoch DJ, Dolan A, Donald S, Rixon FJ. 1985. Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. J. Mol. Biol. 181:1-13
55. Mellerick DM, Fraser NW. 1987. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology 158:265-75
56. Montgomery RI, Warner MS, Lum BJ, Spear PG. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-36
57. Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, et al. 2000. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther. 7:1483-90
58. Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, et al. 1998. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res. 58:5731-37
59. Mu X, Silos-Santiago I, Carroll SL, Snider WD, 1993. Neurotrophin receptor genes are expressed in distinct patterns in developing dorsal root ganglia. J. Neurosci. 13:4029-41
60. Natsume A, Mata M, Goss JR, Huang S, Wolfe D, et al. 2001. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA induced degeneration. Exp. Neurol. 169:231-38
61. Natsume A, Mata M, Wolfe D, Oligino T, Goss J, et al. 2002. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect. J. Neurotrauma 19:61-68
62. Natsume A, Wolfe D, Hu J, Huang S, Puskovic V, et al. 2003. Enhanced functional recovery after proximal nerve root injury by vector-mediated gene transfer. Exp. Neurol. 184:878-86
63. Newcomb WW, Homa FL, Thomsen DR, Trus BL, Cheng N, et al. 1999. Assembly of the herpes simplex virus procapsid from purified components and identification of small complexes containing the major capsid and scaffolding proteins. J. Virol. 73:4239-50
64. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, et al. 2000. Effective treatment of experimental glioblastoma by HSV vector-mediated TNFα and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol. Ther. 2:114-20
65. Niranjan A, Wolfe D, Tamura M, Soares MK, Krisky DM, et al. 2003. Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol. Ther. 8:530-42
66. Palmer JA, Branston RH, Lilley CE, Robinson MJ, Groutsi F, et al. 2000. Development and optimization of herpes simplex virus vectors for multiple longterm gene delivery to the peripheral nervous system. J. Virol. 74:5604-18
67. Peltier AC, Russell JW. 2002. Recent advances in drug-induced neuropathies. Curr. Opin. Neurol. 15:633-38
68. Pradat PF, Kennel P, Naimi-Sadaoui S, Finiels F, Scherman D, et al. 2002. Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Ther. 9:1333-37
69. Preston C, Frame M, Campbell M. 1988. A complex formed between cell components and an HSV structural polypeptide binds to a viral iminediate early gene regulatory DNA sequence. Cell 52:425-34
70. Puskovic V, Wolfe D, Goss J, Huang S, Mata M, et al. 2004. Prolonged biologically active transgene expression driven by HIV LAP2 in brain in vivo. Mol. Ther. 10:67-75
71. Puvion-Dutilleul F, Pichard E, Leduc EH. 1985. Influence of embedding media on DNA structure in herpes simplex virus type 1. Biol. Cell 54:195-98
72. Quasthoff S, Grosskreutz J, Schroder JM, Schneider U, Grafe P. 1995. Calcium potentials and tetrodotoxin-resistant sodium potentials in unmyelinated C fibres of biopsied human sural nerve. Neuroscience 69:955-65
73. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, et al. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7:859-66
74. Roizman B, Sears A. 1996. Herpes simplex viruses and their replication. In Fields Virology, ed. BN Fields, DM Knipe, PM Howley, RM Chanock, MS Hirsch, et al., pp. 2231-95. Philadelphia, PA: Lippincott-Raven
75. Sawtell NM, Thompson RL. 1992. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66:2150-56
76. Shibata M, Murray M, Tessler A, Ljubetic C, Connors T, Saavedra RA. 2000. Single injections of a DNA plasmid that contains the human Bcl-2 gene prevent loss and atrophy of distinct neuronal populations after spinal cord injury in adult rats. Neurorehabil. Neural Repair 14:319-30
77. Smith GA, Enquist LW. 2002. Break ins and break outs: viral interactions with the cytoskeleton of mammalian cells. Annu. Rev. Cell Dev. Biol. 18:135-61
78. Sodeik B, Ebersold MW, Helenius A. 1997. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J. Cell Biol. 136:1007-21
79. Spear PG. 1993. Entry of α herpesviruses into cells. Semin. Virol 4:167-80
80. Spear PG, Eisenberg RJ, Cohen GH. 2000. Three classes of cell surface receptors for orherpesvirus entry. Virology 275:1-8
81. Stevens JG. 1989. Human herpesvisruses: a consideration of the latent state. Microbiol. Rev. 53:318-32
82. Stevens JG, Cook ML. 1971. Latent herpes simplex virus in spinal ganglia of mice. Science 173:843-45
83. Tenser RB, Hay KA, Edris WA. 1989. Latency-associated transcript but not re-activatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1. J. Virol. 63:2861-65
84. Valyi-Nagy T, Deshmane S, Dillner A, Fraser NW. 1991. Induction of cellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex virus type 1 infection, and explantation of trigeminal ganglia. J. Virol. 65:4142-52
85. 134.5 deletion mutants in rodent models. J. Clin. Invest. 91:2837-43
86. Yamada M, Natsume A, Mata M, Oligino T, Goss J, et al. 2001. Herpes simplex virus vector-mediated expression of Bcl-2 protects spinal motor neurons from degeneration following root avulsion. Exp. Neurol. 168:225-30
87. Yamada M, Oligino T, Mata M, Goss JR, Glorioso JC, Fink DJ. 1999. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine- induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. USA 96:4078-83